Qube Research & Technologies (QRT)
UTHR icon

Qube Research & Technologies (QRT)’s United Therapeutics UTHR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.2M Buy
123,441
+25,137
+26% +$12.5M 0.08% 307
2025
Q4 		$47.9M Buy
98,304
+68,705
+232% +$32M 0.05% 515
2025
Q3 		$12.4M Sell
29,599
-121,496
-80% -$40.9M 0.01% 1185
2025
Q2 		$43.4M Sell
151,095
-31,495
-17% -$9.41M 0.04% 525
2025
Q1 		$56.3M Buy
182,590
+72,247
+65% +$24.8M 0.07% 370
2024
Q4 		$38.9M Buy
110,343
+56,530
+105% +$20.8M 0.05% 467
2024
Q3 		$19.3M Buy
53,813
+22,118
+70% +$7.47M 0.03% 691
2024
Q2 		$10.1M Sell
31,695
-152,962
-83% -$40.5M 0.02% 916
2024
Q1 		$42.4M Sell
184,657
-20,587
-10% -$4.65M 0.07% 346
2023
Q4 		$45.1M Buy
205,244
+121,279
+144% +$28M 0.09% 288
2023
Q3 		$19M Buy
83,965
+4,245
+5% +$978K 0.05% 429
2023
Q2 		$17.6M Sell
79,720
-96,447
-55% -$21.4M 0.06% 371
2023
Q1 		$39.5M Buy
176,167
+31,211
+22% +$7.69M 0.17% 129
2022
Q4 		$40.3M Buy
144,956
+77,946
+116% +$19.7M 0.22% 109
2022
Q3 		$14M Buy
+67,010
New +$15M 0.08% 325
2022
Q2 		– Sell
-15,557
Closed -$2.79M – 3159
2022
Q1 		$2.79M Buy
+15,557
New +$2.96M 0.02% 697
2021
Q4 		– Sell
-66,113
Closed -$12.2M – 2990
2021
Q3 		$12.2M Buy
66,113
+51,904
+365% +$10.2M 0.15% 160
2021
Q2 		$2.55M Buy
14,209
+6,505
+84% +$1.24M 0.03% 619
2021
Q1 		$1.29M Buy
+7,704
New +$1.28M 0.02% 756
2020
Q4 		– Sell
-48,259
Closed -$4.87M – 2230
2020
Q3 		$4.87M Buy
48,259
+4,995
+12% +$548K 0.07% 364
2020
Q2 		$5.24M Buy
+43,264
New +$4.87M 0.08% 336
2018
Q4 		– Sell
-1,440
Closed -$184K – 873
2018
Q3 		$184K Buy
1,440
+1,008
+233% +$125K 0.02% 536
2018
Q2 		$49K Buy
+432
New +$47.5K 0.03% 528

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Qube Research & Technologies (QRT)'s UTHR Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its United Therapeutics (UTHR) stake by 26% in Q1 2026, buying an estimated $12.5M and bringing the position to 123,441 shares worth $73.2M. The position accounts for 0.08% of the portfolio, ranked #307.

Qube Research & Technologies (QRT) first reported a position in UTHR in Q2 2018 and has held it in 23 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Qube Research & Technologies (QRT) held 123,441 shares of United Therapeutics worth $73.2M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 25,137 United Therapeutics shares in Q1 2026, an estimated $12.5M.
  • United Therapeutics made up 0.08% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #307 holding.
  • Qube Research & Technologies (QRT) first reported a position in United Therapeutics in Q2 2018 and has held it in 23 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.